Prophylactic preoperative levosimendan administration in heart failure patients undergoing elective non-cardiac surgery: A preliminary report

Hellenic Journal of Cardiology

Volumn 50, Issue 3, 2009, Pages 185-192

  Katsaragakis, Stilianos ^a   Kapralou, Athina ^a   Drimousis, Panagiotis ^a   Markogiannakis, Haridimos ^a,b   Larentzakis, Andreas ^a   Kofinas, George ^a   Misthos, Panagiotis ^a   Filis, Konstantinos ^a   Theodorou, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Elective non cardiac surgery; Heart failure; Inotropes; Postoperative cardiac complications; Prophylactic preoperative levosimendan administration

Indexed keywords

LEVOSIMENDAN;

ABDOMINAL SURGERY; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; ELECTIVE SURGERY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HYPOTENSION; LUNG ARTERY CATHETER; MALE; PATIENT MONITORING; PREOPERATIVE CARE; SYSTEMIC VASCULAR RESISTANCE; TACHYCARDIA;

AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; GREECE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PREVALENCE; PROSPECTIVE STUDIES; PYRIDAZINES; SURGICAL PROCEDURES, ELECTIVE; TREATMENT OUTCOME;

EID: 66949165907     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mercado DL, Ling DY, Smetana GW. Perioperative cardiac evaluation: novel interventions and clinical challenges. South Med J. 2007; 100: 486-492. (Pubitemid 46707450)
2. Toller WG, Metzler H. Acute perioperative heart failure. Curr Opin Anaesthesiol. 2005; 18: 129-135. (Pubitemid 40523224)
3. Toufektzian L, Theodorou D, Larentzakis A, Misthos P, Katsaragakis S. Optimization of cardiac performance in chronic heart failure patients undergoing elective non-cardiac surgery. Curr Anaesth Crit Care. 2007; 18: 50-57. (Pubitemid 46994595)
4. Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol. 2004; 44: 1446-1453. (Pubitemid 39303947)
5. Gelow JM, Fang JC. Update in the approach to and management of heart failure. South Med J. 2006; 99: 1346-1355. (Pubitemid 46035553)
6. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994; 330: 1717-1722. (Pubitemid 24171030)
7. Moiseyev VS, Põder P, Andrejevs. N, et al; RUSSLAN Study Investigators: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23: 1422-1432.
8. Todaka K, Wang J, Yi GH, et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther. 1996; 279: 120-127. (Pubitemid 27166902)
9. Follath F, Cleland JG, Just H, et al; Steering Committee, Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360: 196-202.
10. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy. 2004; 24: 1366-1384. (Pubitemid 39305000)
11. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007; 104: 766-773. (Pubitemid 46548294)
12. Bredin F, Franco-Cereceda A. Experiences of levosimendan as an inotropic agent in conjunction with passive containment surgery. Scand Cardiovasc J. 2007; 41: 197-200. (Pubitemid 46784853)
13. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999; 34: 219-228. (Pubitemid 29350503)
14. Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol. 2007; 48: 80-88. (Pubitemid 47621098)
15. Siirilä-Waris K, Suojaranta-Ylinen R, Harjola VP. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth. 2005; 19: 345-349. (Pubitemid 40797692)
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60: 646-649.
17. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977; 297: 845-850. (Pubitemid 8200494)
18. The criteria committee of the New York Heart Association. Nomenclature and Criteria for diagnosis, 9th edition. Boston: Little Brown (Publishers); 1994.
19. American Society of Anesthesiologists. New classification of physical status. Anesthesiology. 1963; 24: 111.
20. Belzberg H, Rivkind AI. Preoperative cardiac preparation. Chest. 1999; 115 (5 Suppl): 82S-95S. (Pubitemid 29228264)
21. Boersma E, Poldermans D, Bax JJ, et al; DECREASE Study Group (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). Predictors of cardiac events after major vascular surgery: Role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA. 2001; 285: 1865-1873.
22. Romero L, de Virgilio C. Preoperative cardiac risk assessment: an updated approach. Arch Surg. 2001; 136: 1370-1376. (Pubitemid 33120940)
23. Flancbaum L, Ziegler DW, Choban PS. Preoperative intensive care unit admission and hemodynamic monitoring in patients scheduled for major elective noncardiac surgery: a retrospective review of 95 patients. J Cardiothorac Vasc Anesth. 1998; 12: 3-9. (Pubitemid 28128416)
24. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995; 27: 1859-1866.
25. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des. 2005; 11: 435-455. (Pubitemid 40220268)
26. Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol. 2005; 99: 409-413. (Pubitemid 40363991)
27. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004; 93: 1309-1312. (Pubitemid 38595693)
28. Parissis JT, Panou F, Farmakis D, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005; 96: 423-426. (Pubitemid 41058875)
29. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail. 2005; 7: 882-887. (Pubitemid 41125911)
30. Nanas JN, Papazoglou P, Tsagalou EP, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol. 2005; 95: 768-771. (Pubitemid 40332658)
31. Nanas JN, Papazoglou PP, Terrovitis JV, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol. 2004; 94: 1329-1332. (Pubitemid 39469964)
32. Dernellis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest. 2005; 128: 2633-2639. (Pubitemid 41507621)
33. McLean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol. 2005; 46: 830-835. (Pubitemid 44378257)
34. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006; 98: 102-106. (Pubitemid 43902695)
35. Trikas A, Antoniades C, Latsios G, et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail. 2006; 8: 804-809. (Pubitemid 44779417)
36. Mavrogeni S, Giamouzis G, Papadopoulou E, et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail. 2007; 13: 556-559. (Pubitemid 47362748)
37. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007; 21: 431-435. (Pubitemid 350231513)
38. Ponschab M, Hochmair N, Ghazwinian N, Mueller T, Plöchl W. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair. Eur J Anaesthesiol. 2008; 25: 627-633.
39. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005; 294: 1625-1633. (Pubitemid 41407355)